title: Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial.
abstract: Although a number of studies have investigated and quantified immune correlates of protection against influenza in adults and children, data on immune protection in the elderly are sparse. A recent vaccine efficacy trial comparing standard-dose with high-dose inactivated influenza vaccine in persons 65 years of age and older provided the opportunity to examine the relationship between values of three immunologic assays and protection against community-acquired A/H3N2 influenza illness. The high-dose vaccine induced significantly higher antibody titers than the standard-dose vaccine for all assays. For the hemagglutination inhibition assay, a titer of 40 was found to correspond with 50% protection when the assay virus was antigenically well matched to the circulating virus--the same titer as is generally recognized for 50% protection in younger adults. A dramatically higher titer was required for 50% protection when the assay virus was a poor match to the circulating virus. With the well-matched virus, some protection was seen at the lowest titers; with the poorly matched virus, high levels of protection were not achieved even at the highest titers. Strong associations were also seen between virus neutralization test titers and protection, but reliable estimates for 50% protection were not obtained. An association was seen between titers of an enzyme-linked lectin assay for antineuraminidase N2 antibodies and protection; in particular, the proportion of treatment effect explained by assay titer in models that included both this assay and one of the other assays was consistently higher than in models that included either assay alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01427309.).
authors.affiliation: Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Dunning
authors.affiliation: Sanofi Pasteur, Swiftwater, Pennsylvania, USA carlos.diazgranados@sanofipasteur.com.
authors.forename: Carlos A
authors.initials: CA
authors.lastname: DiazGranados
authors.affiliation: Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Voloshen
authors.affiliation: Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
authors.forename: Branda
authors.initials: B
authors.lastname: Hu
authors.affiliation: Sanofi Pasteur, Swiftwater, Pennsylvania, USA.
authors.forename: Victoria A
authors.initials: VA
authors.lastname: Landolfi
authors.affiliation: Vanderbilt University Medical Center, Nashville, Tennessee, USA.
authors.forename: H Keipp
authors.initials: HK
authors.lastname: Talbot
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood*; D004311:Double-Blind Method; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D009439:Neuraminidase / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; D009439:Neuraminidase